Nobilon advances intranasal seasonal influenza vaccine into proof of concept study

16-Oct-2009 - Nobilon, the human vaccine business unit of Schering-Plough Corporation, announced that it has initiated a clinical Proof of Concept trial with SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use. “We are encouraged by the continuation of the clinical ...

Nobilon advances first vaccine into human trials

Intranasal influenza vaccine begins Phase I clinical development

16-Mar-2009 - Nobilon, the human vaccine business unit of Schering-Plough Corporation, announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal ...

European expert consortium combines forces to develop a novel pandemic influenza vaccine

28-Sep-2007 - A consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four-year project has been awarded a grant of EUR3.5 million from the European Union to help fund the ...

Nobilon acquires rights to EBx cell lines from Vivalis for development, production and marketing of influenza vaccines

01-Jun-2007 - Nobilon and Vivalis announced that Nobilon (part of Organon, the human healthcare business unit of Akzo Nobel) has acquired rights from Vivalis to its EBx® cell lines (derived from avian embryonic stem cells) and related technology platform for the development, production and marketing of human ...

Organon BioSciences appoints Joost Helsen as General Manager of Nobilon

10-Nov-2006 - Joost Helsen has been appointed General Manager of Nobilon, the human vaccines business of Organon BioSciences. Nobilon is a key strategic initiative, founded in 2002, that bridges Intervet's expertise in vaccine development with Organon's ability to register and market human health care ...

Nobilon receives European GMP approval for production of Influenza vaccines for clinical trials

20-Oct-2005 - Nobilon International obtained a European Good Manufacturing Practice (GMP) approval to produce human influenza vaccines for use in clinical trials. The approval was granted recently by the Dutch Ministry of Public Health following a mandatory inspection of the company's premises in Boxmeer, the ...